Prempro news | Breaking Prempro news | Prempro

Wyeth Reports Results for the 2004 Fourth Quarter and Full Year

... A direct-to-consumer advertising campaign was launched in 2004 featuring The national television campaign and print campaign educates women about the appropriate use of hormone therapy and encourages dialogue between women and their health care professionals about the treatment of menopausal symptoms.Also contributing to Wyeth's growth in 2004 was ZOSYN.

Zosyn remains the second largest selling and fastest growing broad-spectrum I.V.

antibiotic globally.

Net revenue increased 19% to $760 million for the year, reflecting growth in both the U.S.

and internationally.Building on the success of Zosyn, Wyeth submitted a global registration dossier for the investigational antibiotic TYGACIL (tigecycline) in the fourth quarter.

On January 28, 2005, Wyeth announced that the FDA granted priority review status to the Company's New Drug Application (NDA) for Tygacil.

A priority designation can be given to an NDA for a drug that, if approved, would be a significant improvement compared with existing treatments.Wyeth is seeking market approval for Tygacil as a single agent therapy to treat patients with complicated intra-abdominal infections (cIAI) and complicated skin and skin structure infections (cSSSI), caused by gram-negative and gram-positive pathogens, anaerobes, and both methicillin-susceptible and methicillin-resistant strains of Staphylococcus aureus (MSSA and MRSA).

Complicated infections and antibiotic resistance are serious concer...

Appeals court upholds lower court ruling against local company

...About two dozen workers lost their jobs as a result.

Email this story Post a comment Print this story Published: Jan 27, 2005 - 10:00:13 am CST News Index Local officials react to Pawlenty budgetOutlet owner awaits verdictCrash kills twoAppeals court upholds lower court ruling against local companyBenefit, fund-raisers and comedy on tap for weekend Copyright © 2005 Albert Lea Tribune Inc.

All rights reserved.

A Boone Newspapers Inc.

publication.

...

Caring for 'pre-osteoporosis'

...My gynecologist thought the risks were minimal, but prescribed Fosamax in place of the hormones for osteoporosis prevention.

When I began to have difficulty swallowing, he switched me to Actonel, which I recently stopped taking because of heartburn.

Currently, I take 1,000 mg of Viactiv daily plus a multivitamin with 200 mg of calcium.

I also exercise, drink milk and eat yogurt and lots of vegetables.

My question is, now what?

Would a lower dose of hormone therapy be the less risky route?

It's very hard for a layperson to know what to do given all the information (and misinformation) out there.

Maybe other postmenopausal women would be interested in your response.

A: You can bet a legion of other women share your place.

The osteopenia in your hip (indicating loss of bone mass) might be thought of as "pre-osteoporosis." Fosamax and Actonel, called bisphosphonates, gradually increase bone mass and reduce fracture risk.

The downside is that these drugs can damage the food tube (esophagus) unless they're taken exactly as directed.

They are poorly tolerated in people with GERD (gastroesophageal reflux disease), which causes acidic stomach contents to back up into the food tube.

GERD is fairly common in elderly people.

You might be more likely to tolerate the once-weekly version of Fosamax or Actonel.

Or, if you'd rather try estrogen again, you could ask your doctor a...

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | All news

Health and Fitness